Received: 10 November 2020
Accepted: 14 December 2020
First Online: 8 April 2021
Ethics approval and consent to participate
: The institutional review board of the hospital approved the study, and written informed consent was obtained from the patients (clinical study number, UMIN000028756: an exploratory clinical trial on the safety of combination therapy with effector cell therapy and immune checkpoint inhibitors for patient with malignant tumor).
: Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: The authors declare that they have no competing interests.